Stadexmin combines the anti-inflammatory and anti-allergic effects of the corticosteroid betamethasone, a synthetic derivative of prednisolone with the antihistaminic activity of dexchlorpheniramine maleate.

Pack size Box of 100 tablets. Bottle of 100 tablets, 200 tablets, 500 tablets
Shelf-life 24 months
Composition Betamethasone; Dexchlorpheniramine maleate
Dosage forms and strengths Tablet: Betamethasone 0.25 mg; Dexchlorpheniramine maleate 2.0 mg
Product code :



Treatment of difficult cases of respiratory, dermatologic and ocular allergies, as well as ocular inflammatory disorders, where adjunctive systemic corticosteroid therapy is indicated.


  • Adults and children > 12 years:
    Initial with 1-2 tablets 4 times daily, after meals and at bedtime. Do not exceed 8 tablets daily.
  • Children 6-12 years:
    ½ tablet 3 times daily. An additional daily dose is required if necessary. Do not exceed 4 tablets daily.


Stadexmin is orally administered, it should be taken preferably at bedtime.

  • Patients with known hypersensitivity to any of the ingredients.
  • Children under 6 years.
  • Patients receiving monoamine oxidase (MAO) inhibitors therapy.
  • Patients with systemic fungal infections.
  • Gastro-duodenal ulcer.
  • Narrow-angle glaucoma.
  • Prostatic hypertrophy or bladder neck obstruction.


  • Sodium retention and fluid retention;
  • Increased excretion of potassium;
  • Menstrual irregularities, Cushing’s syndrome, growth retardation in children, decreased glucose tolerance, manifestations of latent diabetes mellitus;
  • Muscle atrophy, muscle weakness, osteoporosis, pathologic fracture of bone, particularly vertebral fractures, aseptic necrosis of femoral heads.
  • Drowsiness, sedation.
  • Dry mouth.

Stadexmin contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Stadexmin contains the azo colouring agents e.g., sunset yellow and ponceau 4R, which may cause allergic reactions.

Extreme caution should be exercised when use Stadexmin for:

  • The elderly (> 60 years) and children.
  • Pregnancy and breastfeeding women.
  • Patients with congestive heart failure, recent myocardial infarction, or hypertension, in patients with diabetes mellitus, epilepsy, glaucoma, hypothyroidism, hepatic failure, osteoporosis, peptic ulceration, psychoses or severe affective disorders, and renal impairment.
  • Patients with non-immune with chickenpox, herpes zoster and measles.
  • Patients with angle-closure glaucoma, urinary retention, prostatic hyperplasia, or pyloroduodenal obstruction due to its anticholinergic adverse effects.

Stadexmin is not recommended in the presence of acute infections uncontrolled by appropriate antimicrobial therapy, patients with active or doubtfully quiescent tuberculosis. Live vaccines should not be given to patients receiving Stadexmin nor for at least 3 months afterwards; killed vaccines or toxoids may be given although the response may be attenuated.

During prolonged Stadexmin using, patients should be examined regularly. Sodium intake may need to be reduced and calcium and potassium supplements may be necessary.

Stadexmin can cause drowsiness, dizziness and psychomotor impairment in some patients. This is accentuated by taking alcoholic beverages or medicines containing alcohol or other sedatives. Stadexmin should be avoided when driving and controlling machine.